Table Of Content

SUBJECT INDEX Aprotinin Blood conservation in liver transplantation 595 Blood culture systems renal risk in cardiac surgery and 2207 (1 Blood donation. See Donation; Predonation screening vs. tranexamic acid in cardiac surgery 31 90k Blood donors. See Donors 2208(L), 2209(R Blood drives Aralast 1959 Blood group typing Arsine toxicity 1267, 1576 agglutination in Arterial blood gases 186 cold agglutinins and Asian population 2128 dispermic chimerism in ATP mixed-field agglutination reaction PLT storage and preoperative RBC storage and Blood irradiation quality control Autoimmune hemolytic anemia 90, 741, 1859 Blood pressure, in repeated autologous blood donation Autologous blood donation Blood saving protocol baboon 8S:1S Blood substitutes cord RBCs 1049 Blood transfusion in-line filtration 811 allogeneic (See Allogeneic blood transfusion preoperative 934, 1484 autologous (See Autologous blood donation re peated blood pressure 934 historical asepcts rHu-EPO therapy 1616 mismatched, for autoimmune hemolytic anemia RBCs (See RBC transfusions B risk management B cell recovery,from leukodepletion filters j unmatched, decreased immunorejection B gene 1988 for very-low-birth weight infants B19 genotype 3, 1593 Blood transfusion refusal B19 virus 1143, 1162, 1593, 1648(1 Blood viscosity Bacillus cereus Blood volume changes, during cardiac surgery buffy coat storage 949 Bloodless medicine detection methods Bloodletting BacT/ALERT culture system BNP Bacterial artificial chromosomes Body weight, donor reaction rates Bacterial contamination Bombay phenotype ATR in PICU 1899 Bone marrow transplantation, allogene donor evaluation 649 ABO-mismatched of PCs 41, 220, 636, 649, 719, 949 IVIG usage platelet senescent cultures National Marrow Donor Program rapid detection methods Book reviews surveillance methods Brazilian population Bacterial detection methods Breast cancer culturing Buffering, in RBC storage in PCs Burn shock resuscitation Bacterial inactivation. See Pathogen inactivation methods Bacterial infections. See also specific bacteria granulocyte transfusions for 1909 alcium chloride BAGPM 1469(F anada Bar code patient identification system Canadian Consensus Conference 1465 Basal cell adhesion molecule 668 donor health assessment questionnaire 2169 Bedsite filtration 896 HCV lookback studies 690 §3-Integrin 780 ancer patients 668, 1199 Bioterrorism agents 78(L), 1589 ardiac surgery Biotin labeling, of RBCs 578 antithrombin during 1130 Bleeding apoprotin vs. tranexamic acid in } 327, 2208(1 in acute leukemia 2209(R gastrointestinal clinical prediction rule for allogeneic blood during liver transplantation transfusion self-assessment 1926 fatal TA-GVHD Bleeding time 731, 88:18 leukoreduction in Blood banks need for transfusion cord blood unit characteristics 1190 RCV during mistransfusion risk 1085 ardiopulmonary bypass surgery operating theater blood transaction system antithrombin for quality control Hct transfusion trigger Blood bottles RCV during Blood cell preparations/ products. See also specific blood cell arriers preparations/products HBsAg 2047 for coagulopathy of trauma 685(1 arriers, HCMV GN-genotypes in monocytes 1754 quality 118 atheter-related complications 154(1 Blood centers aucasian population physicians role in 854 adverse donor reactions 03011 PLT production and discard rates 991 idverse reactions in adolescent donors 2030(1 Blood clots, in RBCs 1646(1 protein RBC antigen immunogenicity 1328 Blood component preparation Cls 1306 comparison of technical efficiency 2100 CR7 expression 1494 Volume 46, December 2006 TRANSFUSION 2223 SUBJECT INDEX CD55 Cord blood CD83 CD177 expression CD133+ characteristics CD177 engraftment potential CD34+ cells National Marrow Donor Program in cord blood ransplant outcomes leukapheresis initation and in vitro assays of he matopoietic cells quantification ord blood transfusion recovery from whole-blood filters adult recipient outcomes CD34+ cell counts autologous CD34+ cell mobilization telomere during apheresis oronary artery bypass grafting with chemotherapy plus growth factors aprotinin vs. tranexamic acid in in heart failure leukoreduction in long-term engraftment capacity and RBC storage time and in multiple myeloma ost effectiveness analyses with rHUG-CSI ounseling, physicians role i serum-free mediun rawtord antigen + cells reutzfeldt-Jakob disease CD4+ cells, CMV-specific donor deferral policies CD8+ cells leukodepletion and CD14+ cells prion removal/ inactivation from blood components CD16+ cells iil CD19+ cells romer antige CD45+ cells ross-reactivit\ CD47 expression ryopoor-plasma CD177 expression yopreservalior CD11b up regulation yclophospnhan ceCl Cell-associated activel Cell-free virus eRA ceRT phenotype CFU-GM Chagas disease Chemotherap\ Chicken anemia virus ina hildren. See Pediatri« himerism hinese blood donors hitotriosidase hloride, in RBC storage hronic graft-versus-h« IDP irrhosis itrate phosphate ¢ ladribine-related CLI Clotting factors. Se CMV HCMV GN-ge in vitro mode Coagulation factors. See mild abnormali in PCT-treated plasn proteomic ana Coagulopathy rFVila therapy of trauma patient Cobe Spectra continuous-flow ll separate Cold agglutinins Collection volume, donor reaction rates Compatibility testing, for same-day surge CompoDock 82 sterile connection device Compound adsorption device COM.TEC cell separator Confidentiality, refusal of blood transfusion Contingency planning, refusal of blood transfusic Continuous ambulatory blood pressure monito PABD Coombs, Robert Royston Amos (Robin 2224 TRANSFUSION Volume 46, December 2006 SUBJECT INDEX Documentation, of transfusion refusal Elastase Dombrock blood group system Elderly TA-GVHD Donation ELISA 1utologous preoperative (See Autolblooogd odonuatsio n anti-HC\ barriers to Chagas disease decision-making IgA-deficient blood donor registry eating before neopterin during HBV window-period Trypanosoma cru psychological aspects 006 ume 99 E-mail recruitment vhole-blood, menstruating females and 667 ndothelial progenitor cells Donor history questionnaire, abbreviated 45 ngraftment potential, cord blood Donor lymphocyte collections nhanced Bacterial Detection System Donor recruitment pidemiologic investigations, of infected blood don advertising pstein-Barr virus African Americans rythrophagocytosis donation decision and rythropoiesis MSM deferral criteria rythropoietir randomized controlled trials strategies i Tl risk in Chinese donors Donor registry Donor return rates adverse events and decision to donate and phlebotomist interpersonal skill predonation anxiety rs. See aiso Predonation screening 1dverse reactions blood volume regulation Canadian donor health assessment questionnaire Chinese, TTI risks Volume 46, December 2006 TRANSFUSION 2225 SUBJECT INDEX early phase infection, neopterin levels in 1886 G829A muiation .. (nila vialiashaideiniie ional 780 health-related quality of life 278 Gambro Trima Accel . 2 vessen, BOO lookback studies 690 Gamma irradiation. ....... aieans 34, 800 predonation screening 1380, 2033(¢ Gastrointestinal bleeding sin . 919 serologic assays, cross-reactivity 1847 (1 Gastrointestinal reflux disease ........... 1537 Health-reiated quality of life Gaucher disease .......... nana sii . 1705 Heart failure G-CSF granuloctye stimulation Heat treatment, SARS-CoV inactivation mobilized granulocyte transfusions 1849(1 Hematocrit 365, 1892 G-CSF granulocyte stimulation ..... 1(E Hematomas 2184 CD34+ yield, dose and sae 180 Hematopoietic cells in heart failure ... ‘ 1424 recovery, ABO-mismatched BMT for hemoprotenitor cell transplantation 14, 186 stem cell transplants 14, 169, 186, 1038 for pediatric patients .. ‘ 1909 in vitro cord blood assays 198(I respiratory disturbances : .. 186 Hemoglobin-vesicles GeneScan fragment analysis : 1259(1 Hemolysis Genotyping after ATG 1245 ABO ATR in PICU 1899 in sickle cell anemia 105 HNA-5a Hemolytic anemia, lgM-mediated Kell Hemolytic disease of fetus and newborn SSP anti-Di Gen-Probe RhIG prophylaxis German population Hemolytic transfusion reactions Glucose, in stored PLTs 942 Hemorrhage, fetomaternal Glutathione S-transferase T1 1505 Hemostasis, by rehydrated lyphilized PLTs Glycoproteins Hemotherapy IBo 2090 Heparin Kell 1879 Hepatectomy, partial Lutheran 668 Hip surgery Glycosorb ABO column 1568 Histoplasmosis Glycosphingolipids, in NOR RBCs 1264(1 History of transfusion medicine Granulocyte collection blood bottles Granulocyte transfusions blood grouping after allogeneic transplant blood transfusions dose direct transfusions G-CSF stimulation (See G-CSF stimulation medical photography pediatric ‘ HIV GSTT1 antigen differential transmission Guillian-Barre syndrome early phase infection Hb levels with positive DAT IVIG usage Haemonetics MCS Plus predonation screening HA-1" cytotoxic T cells serologic assays, cross-reactivity HAV transfusion risks Hb \ antibody prevalence decrease \ class Il restriction analysis in HIV+ patients with positive DAT \ haplotype in RBC units A typing regeneration after donation A-DR in sickle cell anemia A-matched PLTs, shipping in whole-blood donors 2176 HNA-4a antigen Hb-based oxygen carriers l 3 HNA a antigen HBsAg Hold time, before PRP processing HBV Hospital transfusion services donor deferral ) HPA-la in Dutch donors V2 HTLV early phase infection in Dutch donors NAI lookback program posttransfusion hepatitis serologic assays, Cross-reactivity quantificaton and infectivity serologic tests serologic assays, cross-reactivity Human serum albumin. See Albumin, human serun window-period blood donation Hydroxyethyl starch Hb-vesicles Hyperbilirubinemia HCMV GN-genotypes Hyperhemolysis Hct-to-viscosity ratio of RBCs Hypertension HCV Hypertriglyceridemia antigen testing in pools Hypervariable regions assays Hypogammaglobulinemia childhood-acquired Hypotension demographic correlates of viremia Hypothermia donor deferral Hypotonic shock response in Dutch donors Hypovolemia 365. 8S:1S. 1609 2226 TRANSFUSION Volume 46, December 2006 SUBJECT INDEX LDH, in stored PLTs i phenotype 1982 Leishmania ICU removal by leukodepletion filters acute pediatric transfusion reactions 1899 risk to blood supply PLI transfusions 286 Lenograstim See GCI RBC storage time in CABG Leukapheresis TRALI incidence Leukemia Idiopathic thrombocytopenic purpura Leukoreduction (leukodepletion gA deficiency adhesion of RBC products gA-deficient blood donor registry of autologous whole blood GHV3 superspecies genes 2162 in cardiac surgery igM antibodies 2035 microvesicles and IGnT allele, novel 1982 postoperative infection and 1184 transfusion-associated microchimerism and 184 Leukoreduction filters 494 CD34+ cell recovery 494 Leishmania removal mmunogenicity of RBCs 1526 LEUKOSEP HR¢ 600-C system Immunosorption, of ABO antibodies 568 mononuclear cell recovery Immunurejection 2122 PBMN( recovery from nab phenotype 34 Trypanosoma cruzi removal nconvenience, as donation barriet Leu,,Val mutation nDel assays ifetime transfusion rates nfants Listeria monocytogenes autologous cord blood transfusion Liver biopsy estimating blood needs for iver transplantation IVIG usage antifibrinolytics in Inflammation anti-GSTT1 in Inherited bleeding disorders rFVIila therapy Innovations, in transfusion medicine OCR antigen Inositol hexaphosphate-adenosine triphosphate »-polyethylene Lookback studies glycol Low-molecular-weight heparin Inositol hexaphosphate-polyethylene glycol Lutheran blood group system Integrins Lymphoma INTERCEP! Blood System Lysosomal storag acquired Interlaboratory comparisons International transfusion practice M Intersol Maco Biotech HPO! medium Iron Macrophages absorption 1616 glycoproteoin [Ba in platelet phagoc ytosi 090 depletion 166 PLT binding and phagocytosis 1432 I\ WNV replication in oral supplementation MAIPA assay IR-WP model Malaria lsoelectric :ocusing Manufacturer quality control ITT principle Massachussetts General Hospital IVIG usage IVIG Maternal antigens, noninherited Maternal typing Matrix metalloproteinases Jehovah's Witnesses Medical photog iphy i1n8 55 JK blood group MEHP 03(1 js* anugen Membrane fusion exocytic vesiculation and 1435 Js” antigen Methemoglobinemia LO60(1 Methoxypolyethylene glycol Me XICt KALI transfusion-associated Chagas disease Kawasaki disease WNV cde tection in blood supply Kell blood group system MGDI antigens Microchimerism genotyping assays 1870 RBC alloantibodies 250 630 posttransfusion 1856, 1863 Kidney disease 1104 22 71 Microvesicles Kidney transplantation 905 »bu leukodepletion and Klebsiella pneumoniae RBC storage bulfy coat storage 949 Minisatellite detection methods Mirasol PRT treatment Korean donors Misidentification prevention KTIM Mismatched blood transfusion Kuwaiti population, ABO blood group in Missense mutation 1982 Mistransfusion risk 1085 L Mixed-field agglultination 1463 actate, in stored PLTs Mixed-field agglutination reaction 1463 Latent virus MMN 4] Volume 46, December 2006 TRANSFUSION 2227 SUBJECT INDEX MNS blood group 630 Oo Model systems, CMV 1580 Obituary, Robert Royston Amos (Robin) Coombs 1854 Modified fluid gelatin 1892 Octanoic acid treatment 1770 Molecular investigations, of infected blood donors 1663(E Operating theater blood transaction system 1848(1 Monoclonal antibodies (McAbs 1011, 1444 Orthopedic surgery 1097, 1484 aoa Mononuclear cell counts 498(E), 507 Osteocalcin ) Mononuclear cells Oxygen affinity 8S:1S collection methods 118, 1044, 2083 Oxygen carriers, artificial 1104, 1892 HCMV GN-genotypes Oxygen delivery, RBC storage 2014 Leishmania amastigotes in Mirasol PRT-treated residual RBCs and p24 antigen 1624 WNV replication in Pall Bacterial Detection System 220 Morphine PCA, coadministered with RBC transfusion Pancreatitis 1853 Mortality Para-Bombay phenotype 2149 ATR in PICU , 1899 Parosysmal nocturnal hemoglobinuria 1244 lifetime transfusion rates and 1491 Parvovirus B19 1162, 1593, 1648(1 plasma exchange complications in TTP-HUS 154(1 Paternity tests TA-GVHD 885 demographics and 849 mRNA expression, CD177-specific 132 one- vs. two-parent 199 MSM deferral criteria 869(1 Pathogen inactivation methods MSs blood group system coagulation factors and 1168 mtDNA polymorphisms cost effectiveness 956 Multicomponent apheresis dry-heat 1648(1 Multiple myeloma gamma irradiation 4, 800 Multiple organ dysfunction score resistance 1951 Multiple sclerosis $-303 1I47478R Multiple transfusions, HLA antibody prevalence SARS-Co\ 177 Mutations thiazole orange ABO gene with thiazole orange G829A Patient identificaton bar code system KEI Patient self-assessment, of bleeding symptoms Leu,,;Val Patient-controlled analgesia missense PBPC mobilization platelet §3-integrin gene with chemotherapy and pegfilgrastim Myasthenia gravis in heart failure Myelodysplastic syndrome in multiple myeloma PBPCs recovery from leukodepletion filters NANBH recruitment during apheresis Nanofiltration, antibody-enhanced vield Nasal carriage LYM program NAT. See Nucleic acid testing National Marrow Donor Program CMV model of infection NBI Dombrock blood group assay Necrotizing faciitis HBV quantificaton Need for transfusion, in cardiac surgery novel IGnT allele Neonatal transfusion RT-PCR Neopterin SSP-PCR 780 Netherlands SSS-PCR 1510 bacterial culture and pathogen reductior PCR-RFLP 988 HCV in donors PCT-treated plasma 1168 platelet transfusion safety PCT-treated PLTs | transfusion-transmitted infections in PDGI Neuropathy PDGF-AA Neutropenia, granulocyte transfusion therapy release during platelet storage ] Neutrophil recovery, after chemotherapy Peanut Ingestion 1853 Noncellular blood products, SARS-CoV inactivation Pediatric patients NOR RBCs acute transfusion reactions 1899 Nucleated RBCs acute transfusion reactions in ICU 1899 in cord blood childhood-acquired HCV 1360 flow cytometric evaluation cord blood transplant recipient outcomes 2063 Nucleic acid testing granulocyte transfusions 1909 for bioterror agents HIV/AIDS IVIG usage 741 donors ' 841 very-low-birth weight infants 1915 HBV .. 256, 1886, 2047, 1256 Pegfilgrastim mobilization 180, 141 HCV ‘ ‘ 169, 695, 1822, 1866 Perfluorocarbon emulsion 1892 individual .. ‘ 1138, 2028(1 Peripheral blood progenitor cell transplantation 14, 169, 186 minipool ‘ . 2047 pH predonation screening 1624 intracellular 1029 rapid bacterial detection 1367 PLT storage 871(L), 1300, 942 with serologic tests ....... . 1663(E post-platelet wash WNV (See West Nile Virus NAT RBC storage 2228 TRANSFUSION Volume 46, December 2006 SUBJECT INDEX Phage display technology 1011 sterile connection devices and Phagocytosis 1432, 2090 sterility testing Pharmacist error 682 survival Phenotypes viability assessment ceRT 766 whole-blood derived D antigen 2156 Platelet count AB 780 bleeding and i 1982 neonatal transfusion Para-Bombay 2149 response to PLT transfusion Rh storage of WBC-reduced RBCs and weak ABO 434 Platelet cryopreservation methods Phlebotomist interpersonal skill 1394 Platelet gel formation Phosphate ion-exchange resin 8S:1S Platelet releasate Photochemical treatment Platelet shape with amotosalen and UVA 731, 1168, 1693 Platelet split products Mirasol 642 Platelet storage PLTs 424, 562, 800 ADP response in synthetic media Photopheresis 683 after photochemical treatment Photosensitive dyes buffy coat-derived PCs Phthalates cytokines and Physicians role filter-LR PRP preparations Pica freeze-dried Plasma hold time before adding PAS black 1267 of PCT PLIs muddy” appearance 1060(1 pH platelet ADP response in 204 plasma ectonucleotidases solvent/detergent treatment 2100 postwash PRALI incidence and senescent cultures viscosity temperature volume tum Plasma derivative manufacture Platelet transfusion Plasma exchange idve eactuions arsine toxicity bleec ling outcome in leukemia complications in TTP-HUS vyo ld PCT PLTs hypertriglyceridemia onsistency Plasma proteins, baboon Plasma transfusion therapy neonatal Plasmapheresis ind RBC transfusion for anemic thrombocytopenic DEHP exposure ura with HES practices in Netherland intermittent-flow self-assessment of bleeding LMWH in Streptococcus agalactiae sepsis aftet Plasma-related complications transfusion-transmit Serratia} Platelet activation t-derived mediator Platelet activation inhibition t-derived microvesict Platelet additive solutions tpheresis ADP response 1000 Center rates cytokine levels )EHP exposure hold time PRP-PCs and nts/equipment 1601 storage temperature ingle-needle procedures 1. 2004 storage ume val Charactet ristics Platelet aggregation 1 deviation bag Platelet antibodies Platelet antigens Platelet $3-integrin gene mutation detection ol Jatelet binding hbaboo Platelet concentrate bacteria detection methods bacterial contamination discard rate bacterial detection methods 220, 636 nterctions with DCs 8] buffy coat-derived 949, 99] Listeria monocytogeneisn t05 extended storage Lyphophilized reconstituted 8S:15 flow cytometry-based sterility testing phagocytosis ot 90 lipemic photochemically treated 162, 800 pH production rate 99] photochemical treatment process purinergic receptors 1018 in plasma vs. additive solution rehydrated lyphilized 1029, 1943 platelet-rich plasma method in vivo recovery from PRP washing residual RBCs WB-derived resting time Polycythemia vera shipping effects Polyethylegnley c Staphylococcus aureus—contaminated Polymorphisms Volume 46, December 2006 TRANSFUSION 2229 SUBJECT INDEX Polystyrene alloantibodies Polyvinylchloride alloantigens Porcine circovirus antigens Postoperative length of stay donor molecular profiling Postoperative patients, underestimation of anemia severity in low-frequency Posttransfusion hepatitis autoantibodies PPP depletion, in bone marrow processing Predonation screening exchange, for arsine toxicity abbreviated donor history questionnaire membrane flexibility for bioterror agents microvesicies Canadian donor health assessment questionnaire senescence donor history accuracy storage face-to-face interviewing adhesion to endothelium and HCV infection baboon health history questions buffering and dilution in HIV infection CD47 expression infected donors cold, effect on VWI transfusion risk and consequences in critical illness travel questions, deferral policies and with improved 2,3-DPG WNV microvesiculation Pregnancy quality criteria Premature infants RBC functionality and Preoperative blood sample, expiration date extensior thiazole orange pathogen reduction Prescription medications, donor history accuracy time Prewarming, for Rh antibody testing RBC survival Prion protein affinity ligands baboon Prions in sickle cell anemia PRISIM Chagas assay RBC transfusions Prolastin antifibrinolytics in liver transplantation Propidium iodide-positive events coadministerweidth P¢ Propionibacterium acnes critical illness, storage e ProstaglandinI and PLT transfusion for anemic thrombocytopenic @,-Proteinase inhibitor products purpura 221001 Proteomic analysis trigger, Hct value as Prothrombin complex concentrates low-birth-weight infants PRP-PCs PRV-1 baboon P-selectin expression blood clots in Pseudomonas aeruginosa degliycerolized PT-INR leukoreduced Pulmonary edema postdeg! ycerouzatior Pulsed-field gell electrophoresi quality criteria Purinergic receptors residual in blood products $-303 pathogen inactivation tre% l cell inactivation in Quality vesiculation of autologous whole blood viability of platelets after day storage washing poststorage RBCs WBC reduced WB storage before PRP processing RBV during¢ irdiac surgery Quality control, cord blood REDS-II lbb6SUt Quantification Renal disease 1104 CD34+ cells Research HBV donor 1069(t on infected blood donors 1663(E Nation il Marrow Donor Progran LO80(T Rabbit RBC stroma physicians role in blood center Race Resource utilization donation decision and Respiratory failure HCV RNA negativity Reticulocyte count Radiofrequency identification Reticulocytes, baboon Radiosensitivity of T cells Retrovirus Epidemiology Donor Study Randomized controlled trials Retroviruses amotosalen-treated FFP in TTP RFLP 19 Q5n5 ANH in hip surgery 1097 rFVila 919 donor recruitment strategies 1090 RH43 1334 FOCUS 2192 Rh55 16 39 REDS-II 1663 (1 Rh blood group system SPRINT trial 24, 562 alloimmunization rTP 1659(I antibody testing RANTES 1184 low-incidence antigens Rapid bacterial detection tests 1367 phenotypes RBC adherence, storage duration and 1561 preoperative typing screening 2230 TRANSFUSION Volume 46, December 2006 SUBJECT INDEX RBC alloantibodies in nonhematologic alloimmunized SSCP cohort 630 SSP genotyping weak D cells 1061(1 SSS-PCR RH haplotypes Staphylococcus aureus RH5 variant buffy coat storage RHCE allele detection in PLTs RHCE gene PLT contamination RHD alieles 606 rapid detection methods RhD typing Staphylococcus ¢ pidermidis on cell-free fetal DNA from maternal plasma Sterile connection devices for D- East Asian persons Sterility testing false positive comparisons in southeast Asian populations of platelet concentrates RHD(1T201R,F223V) cluster analysis 606 Streptococcus agalactiae sepsis Rheology 912, 1892 STR-PCR typing RhIG prophylaxis 7 1316, 1652(I Student donor reaction rates rHu-EPO 1616 Surveillance programs rHuG-CSI Swiss population RIBA RIPA Risk profiles, of infected donors 1LACO Risk-behavior reporting TA-GVHD RI R elderly extracorporeal phototherapy Ss fatal S-303 pathogen inactivation treatment prevention Salety laiwan patients abbreviated donor history questionnaire See also specifi acute normovolemic hemodilution HCMV-specific mistransfusion risk radiosensitivity of retroviral lelephone automated system, for risk-behavior reporting rFVila therapy lelomere length changes smallpox vaccination TEPITOPE program Same-day surgery lerumo sterile connection device SARS-CoV inactivation methods letanus toxoid sCD401 Therapeutic plasma exchange. See Plasma exchange scrapie Drain Thrombi: sept shock lhrombocytopenia sequencing alloimmune serologic tests bleeding time correction vith HCV NAT day old PCT PLTs for HTLVs platelet transfusion dose consistency vith NAT lhrombocytopenic purpura for smallpox vaccinees anemic 210(L), 2211 lrypanosoma cruzi idiopathic ‘é rratia marcescens Thrombotic microangiopathy 1221 detection in PLT concentrate lissue culture methods 1494 inactivation during storage INC count 198(1 transfusion-transmitted lforquetenovirus 1593, 1951 Sex, donor reaction rates lotal hip replacement surgery 148 Shipping, of PLTs lotal knee replacement surgery 1112 Sickle cell disease lraining, physicians role in 854 acute chest syndrome PRALI B-CAM/Lu expression BNP measurement 1453(1 educational donor recruitment video endothelial activation 1455(1 Hct-to-viscosity ratio of RBCs epidemiology in ICU 1478 hyperhemolysis incidence 1465 Simian foamy virus infection ranexaMic ac id Skin disinfection method in cardiac surgery ! 2 208(L), 2209(R Smallpox vaccination in liver transplantation SNP lranscription-mediated amplification test Solid organ transplantation lransforming growth factor-6 225, 1184, | false-positive fetal RHD typing lransfusion lookback studies 690 IVIG usage lransfusion medicine history. See History, of transfusion medicine liver lransfusion reactions, acute 1899 Solid-phase scanning cytometer Iransfusion requirement prediction 1120 Solvent-detergent plasma lransfusion Risk Understanding Scoring Tool 1120 Southeast Asian populations lransfusion triggers 365, 1112, 1286 Spanish population lransfusions. See also specific types of transfusions Splenomegaly lransfusion-transmitted infections. See also specific infections Spongiform encephalopathy agents Chagas disease in Mexico 298 removal/inactivation from blood components CMV 889 SPRINT trial erythrovirus B19 1593 Volume 46, December 2006 TRANSFUSION SUBJECT INDEX individual NAT and 2028(1 Venesection Leishmania ‘ 1641 Viability leukodepletion and 407 of apheresis vs. PRP platelets in Netherlands 1729 dendritic cells prion removal/inactivation from blood components 652 of stored RBCs risks in Chinese donors 265 Serratia marcescens 679(1 Viral infections. See also specific viruses and viral infections SFV 352 in deferred donors 1997 viral 624 erythrovirus B19 ; : 1593 West Nile virus 6(I pathogen inactivation (See Pathogen inactivation methods Translation-initiator mutation ‘ 434 retroviruses 1276(E Iransmissible spongiform encephalopathy 152 transfusion-transmitted 1624 [Trauma patients Viscosity, whole blood 1892 coagulopathy of 5(E Volume expanders 1892 posttransfusion microchimerism 856 von Willebrand factor rFVIla therapy 919 cold storage effects 1057 transfusion-associated microchimerism and 863 plasma levels, ABO blood group and 1836 Iravel questions, donor deferrals and 4161 in rehydrated lyphilized PLTs 1943 [riglycerides 853 storage effects 1292 [rima cell separators 966, 2004 in TTP 74 Trypanosoma cruzi 1067, 1737 Irypanosomiasis, American 298 I-sol 800 Ww rTP Waldenstr6m’s macroglobulinemia ADAMTS 13 activity 1444 Warm autoimmune hemolytic anemia amotosalen-treated FFP for 1693 Washing management 687 PLT in pregnancy 1456(1 RBC randomized clinical trials 1659(f activation vWF pathogenicity ir 74 counts rTP-HUS 154(1 inactivation, by Mirasol reduction. See Leukoreduction U Ultralarge von Willebrand factor detection methods Umbilical cord blood. See Cord blood replic ation in monocytes-mac rophages Upshaw-Schulman syndrome self reported symptoms UV irradiation transfusion-associated transmission with amotosalen 1168, 1693 Wound healing, platelet gel for SARS-CoV inactivation Vaccinia viremia rersinia entercolitica Variola virus NAT Vasculogenesis, therapeutic VEGFR-2 Zemaira 2232 TRANSFUSION Volume 46, December 2006